The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Obstructive sleep apnea is associated with higher rates of age-related macular degeneration development and progression.

Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized the management of this progressive and potentially devastating eye disease. These include treatments such as ...

Please provide your email address to receive an email when new articles are posted on . Character Bio is eligible for payments based on future product sales. The collaboration may expand into ...

Age-related macular degeneration (AMD) is the leading cause of vision loss for people over 65. We have excellent treatments for the wet form of AMD. But until recently, we haven’t had any ...

Get Instant Summarized Text (Gist) Once-weekly semaglutide use in individuals with type 2 diabetes more than doubles the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION ...

Genome-wide association analyses identify distinct genetic architectures for age-related macular degeneration across ancestries. Nature Genetics , 2024; 56 (12): 2659 DOI: 10.1038/s41588-024-01764 ...

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...

Anything that tugs on the retina can have this effect. Usually, this is the result of aging, where the vitreous jelly shrinks and pulls away from the back of the eye in a posterior vitreous detachment ...

will debut the beta headset version of its virtual reality smart glasses for people with vision loss related to age-related macular degeneration, according to a press release. “Soliddd’s ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration, a leading cause of blindness in adults over 55. Developed by LumiThera Inc., the device showed ...